Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination

Patients with chronic lymphocytic leukemia (CLL) have an impaired antibody response to coronavirus disease 2019 (COVID-19) vaccination. Here, we evaluated the antibody response to a third BNT162b2 mRNA vaccine in patients with CLL/small lymphocytic lymphoma (SLL) who failed to achieve a humoral resp...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Blood 2022-02, Vol.139 (5), p.678-685
Hauptverfasser:	Herishanu, Yair, Rahav, Galia, Levi, Shai, Braester, Andrei, Itchaki, Gilad, Bairey, Osnat, Dally, Najib, Shvidel, Lev, Ziv-Baran, Tomer, Polliack, Aaron, Tadmor, Tamar, Benjamini, Ohad
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Antibodies, Viral - blood Antibodies, Viral - immunology Antibody Formation BNT162 Vaccine - administration & dosage BNT162 Vaccine - therapeutic use Clinical Trials and Observations COVID-19 - blood COVID-19 - immunology COVID-19 - prevention & control Female Humans Immunity, Humoral Leukemia, Lymphocytic, Chronic, B-Cell - blood Leukemia, Lymphocytic, Chronic, B-Cell - complications Leukemia, Lymphocytic, Chronic, B-Cell - immunology Male Middle Aged SARS-CoV-2 - immunology Vaccine Efficacy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!